These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 24927278

  • 41. Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan.
    Rivory LP, Robert J.
    Cancer Chemother Pharmacol; 1995; 36(2):176-9. PubMed ID: 7767955
    [Abstract] [Full Text] [Related]

  • 42. Method development and validation of the simultaneous determination of a novel topoisomerase 1 inhibitor, the prodrug, and the active metabolite in human plasma using column-switching LC-MS/MS, and its application in a clinical trial.
    Kamei T, Uchimura T, Nishimiya K, Kawanishi T.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Nov 15; 879(30):3415-22. PubMed ID: 21975380
    [Abstract] [Full Text] [Related]

  • 43. Determination of irinotecan and its metabolite SN-38 in dried blood spots using high-performance liquid-chromatography with fluorescence detection.
    Hahn RZ, Arnhold PC, Andriguetti NB, Schneider A, Klück HM, Dos Reis SL, Bastiani MF, Kael I, da Silva ACC, Schwartsmann G, Antunes MV, Linden R.
    J Pharm Biomed Anal; 2018 Feb 20; 150():51-58. PubMed ID: 29216585
    [Abstract] [Full Text] [Related]

  • 44. Quantification of irinotecan, SN38, and SN38G in human and porcine plasma by ultra high-performance liquid chromatography-tandem mass spectrometry and its application to hepatic chemoembolization.
    Chen X, Peer CJ, Alfaro R, Tian T, Spencer SD, Figg WD.
    J Pharm Biomed Anal; 2012 Mar 25; 62():140-8. PubMed ID: 22305081
    [Abstract] [Full Text] [Related]

  • 45. Plasma pharmacokinetics of 7-ethyl-10-hydroxycamptothecin (SN-38) after intravenous administration of SN-38 and irinotecan (CPT-11) to rats.
    Kaneda N, Hosokawa Y, Yokokura T, Awazu S.
    Biol Pharm Bull; 1997 Sep 25; 20(9):992-6. PubMed ID: 9331983
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. A liquid chromatography/electrospray ionization mass spectrometry (LC-MS/MS) assay for the determination of irinotecan (CPT-11) and its two major metabolites in human liver microsomal incubations and human plasma samples.
    D'Esposito F, Tattam BN, Ramzan I, Murray M.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Nov 15; 875(2):522-30. PubMed ID: 18952506
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Simultaneous determination of bentysrepinine (Y101) and its metabolites M8 and M9 in human plasma by UPLC-MS/MS and its application to a pharmacokinetic study.
    Liu X, Huang C, Xue L, Xu Q, Xia W, Li X, Miao L.
    J Pharm Biomed Anal; 2018 Feb 20; 150():287-293. PubMed ID: 29258048
    [Abstract] [Full Text] [Related]

  • 51. Rapid and sensitive determination of vinorelbine in human plasma by liquid chromatography-tandem mass spectrometry and its pharmacokinetic application.
    Qian J, Wang Y, Chang J, Zhang J, Wang J, Hu X.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Mar 15; 879(9-10):662-8. PubMed ID: 21342795
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
    Chabot GG, Abigerges D, Catimel G, Culine S, de Forni M, Extra JM, Mahjoubi M, Hérait P, Armand JP, Bugat R.
    Ann Oncol; 1995 Feb 15; 6(2):141-51. PubMed ID: 7786822
    [Abstract] [Full Text] [Related]

  • 55. [Pharmacokinetics of SN-38 in rats and tissue distribution of 7-ethyl-10-hydroxycamptothecin in mice after intravenous injection of irinotecan hydrochloride nanoparticles].
    Yang FY, Zhang WP, Wang XY, Yang WC, Dang HW.
    Yao Xue Xue Bao; 2014 Jul 15; 49(7):1029-33. PubMed ID: 25233635
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38.
    Chabot GG.
    Cancer Chemother Pharmacol; 1995 Jul 15; 36(6):463-72. PubMed ID: 7554037
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Carboxylesterase and UDP-glucuronosyltransferases mediated metabolism of irinotecan: In vitro and in vivo insights from quantitative ultra-performance liquid chromatography-mass spectrometry analysis.
    Qin Y, Kang A, Zhou G, Wang H, Wei W, Cao Y, Chen Y, Wang J, Shi Y, Tang Y, Jiang J.
    Biomed Chromatogr; 2018 Oct 15; 32(10):e4320. PubMed ID: 29920713
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.